The DOI matches its Crossref record; 86 of the 86 references it cites were found in a registry or an index.
Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Open accessAbstract
INTRODUCTION: To evaluate the efficacy of empagliflozin compared to pioglitazone in patients with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2DM). METHODS: In this prospective randomized, double-blind, placebo-controlled trial, we assigned 106 patients with NAFLD and T2DM to receive empagliflozin 10 mg (n = 35), pioglitazone 30 mg (n = 34), or placebo (n = 37) for 24 weeks. Liver fat content and liver stiffness were measured using fibroscans. Body composition assessment was performed by dual-energy x-ray absorptiometry (DEXA) scans. The primary end point was change from baseline in liver steatosis, using the controlled attenuation parameter (CAP) score. RESULTS: A borderline significant decrease in CAP score was observed with empagliflozin compared to placebo, mean difference: - 29.6 dB/m (- 39.5 to - 19.6) versus - 16.4 dB/m (- 25.0 to - 7.8), respectively; p = 0.05. Using multivariate analysis, we observed a significant reduction in the placebo-corrected change in liver stiffness measurement (LSM) with empagliflozin compared to pioglitazone: - 0.77 kPa (- 1.45, - 0.09), p = 0.02, versus 0.01 kPa (95% CI - 0.70, 0.71, p = 0.98), p for comparison = 0.03. Changes in serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT), fasting insulin, homeostatic model assessment for insulin resistance (HOMA-IR), HOMA2-IR, fibrosis-4 index (FIB4 index), NAFLD fibrosis score, aspartate aminotransferase to platelet ratio index (APRI), android/gynecoid ratio (A/G ratio), and skeletal muscle index (SMI) were comparable between the two treatment groups, while significant reductions of the body weight and visceral fat area were observed only in the empagliflozin group (p < 0.001 and p = 0.01, respectively) and both were increased in the placebo and pioglitazone groups. There were no serious adverse events in either group. CONCLUSION: Treatment for 24 weeks with empagliflozin, in contrast to pioglitazone, was associated with improvement of liver steatosis and fibrosis in patients with NAFLD and T2DM. In addition, body weight and abdominal fat area were decreased in the empagliflozin group. TRIAL REGISTRATION: Iranian Registry of Clinical Trials (IRCT), IRCT20190122042450N3.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Empagliflozin (EMPA), a highly selective inhibitor of sodium-glucose co-transporter 2 (SGLT2), exhibits potential therapeutic benefits for liver steatosis; however, the underlying mechanism remains incompletely elucidated.”
From SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8+ T cell activation (2024) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Sterling, R. K., Lissen, E., Clumeck, N., Sola, R., Correa, M. C., Montaner, J., S. Sulkowski, M., Torriani, F. J., Dieterich, D. T., Thomas, D. L., et al. (2006) · Hepatology · doi:10.1002/hep.21178 · Cited by 5,021 · cited 1×
“Furthermore, the FIB-4 (fibrosis 4) index [39] was calculated using the following formula: FIB-4 index = [age 9 AST (units/l)]/(platelet count (9 10(9)/l) 9 [ALT (units/l)].”
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Angulo, P., Hui, J. M., Marchesini, G., Bugianesi, E., George, J., Farrell, G. C., Enders, F., Saksena, S., Burt, A. D., Bida, J. P., et al. (2007) · Hepatology · doi:10.1002/hep.21496 · Cited by 3,255
Nonalcoholic Fatty Liver Disease: From Steatosis to Cirrhosis
Farrell, G. C., & Larter, C. Z. (2006) · Hepatology · doi:10.1002/hep.20973 · Cited by 2,428
Risk of Cardiovascular Disease in Patients with Nonalcoholic Fatty Liver Disease
Targher, G., Day, C. P., & Bonora, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0912063 · Cited by 1,907
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis
Targher, G., Byrne, C. D., Lonardo, A., Zoppini, G., & Barbui, C. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2016.05.013 · Cited by 1,429
Eddowes, P. J., Sasso, M., Allison, M., Tsochatzis, E. A., Anstee, Q. M., Sheridan, D. A., Guha, I. N., Cobbold, J., Deeks, J. J., Paradis, V., et al. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.01.042 · Cited by 1,425
Cited by
Sorted by citations
Xu, X., Poulsen, K. L., Wu, L., Liu, S., Miyata, T., Song, Q., Wei, Q., Zhao, C., Lin, C., & Yang, J. B. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01119-3 · Cited by 387
Negi, C. K., Babica, P., Bajard, L., Vašků, J. B., & Tarantino, G. (2021) · Metabolism · doi:10.1016/j.metabol.2021.154925 · Cited by 196
SGLT-2 Inhibitors in NAFLD: Expanding Their Role beyond Diabetes and Cardioprotection
Ανδρουτσάκος, Θ., Ansari, N. N., Bakasis, A., Kyrou, I., EFSTATHOPOULOS, E. P., Randeva, H. S., & Kassi, E. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063107 · Cited by 176
Lin, J., Huang, Y., Xu, B., Gu, X., Huang, J., Sun, J., Jia, L., Jiang, H., Huang, C., Wei, X., et al. (2025) · BMJ · doi:10.1136/bmj-2024-083735 · Cited by 147
Shen, Y., Cheng, L., Xu, M., Wang, W., Wan, Z., Xiong, H., Guo, W., Cai, M., & Xu, F. L. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155657 · Cited by 118
Pan, R., Zhang, Y., Wang, R., Xu, Y. Q., Ji, H., & Zhao, Y. (2022) · PLoS ONE · doi:10.1371/journal.pone.0279889 · Cited by 113
Zhang, S., Qi, Z., Wang, Y., Song, D., & Zhu, D. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1203666 · Cited by 87
Lopez, A., & Pajimna, J. A. T. (2024) · Scientific Reports · doi:10.1038/s41598-024-52603-5 · Cited by 91
Moon, J. S., Hong, J. H., Jung, Y. J., Ferrannini, E., Nauck, M. A., & Lim, S. K. (2022) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2022.03.005 · Cited by 76
Pharmacological Approaches to Nonalcoholic Fatty Liver Disease: Current and Future Therapies
Genua, I., & Cusi, K. J. (2024) · Diabetes Spectrum · doi:10.2337/dsi23-0012 · Cited by 74
Abdelhamid, A. M., Saber, S., Youssef, M. E., Gaafar, A. G. A., Eissa, H., Abdel-Dayem, M. A., Alqarni, M., Batiha, G. E., Obaidullah, A. J., Shahien, M. A., et al. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112455 · Cited by 68
SGLT2 inhibitor promotes ketogenesis to improve MASH by suppressing CD8+ T cell activation
Liu, W., You, D., Lin, J., Zou, H., Zhang, L., Luo, S., Yuan, Y., Wang, Z., Qi, J., Wang, W., et al. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2024.08.005 · Cited by 61
Feijóo‐Bandín, S., Aragón‐Herrera, A., Otero-Santiago, M., Anido‐Varela, L., Moraña‐Fernández, S., Tarazón, E., Roselló‐Lletí, E., Portolés, M., Gualillo, O., González‐Juanatey, J. R., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23105634 · Cited by 61
Beygi, M., Ahi, S., Zolghadri, S., & Stanek, A. (2024) · Nutrients · doi:10.3390/nu16142220 · Cited by 69
Bea, S., Ko, H. Y., Bae, J. H., Cho, Y. M., Chang, Y., Ryu, S., Byrne, C. D., & Shin, J. (2024) · Gut · doi:10.1136/gutjnl-2024-332687 · Cited by 60
Wang, Z., Huiqing, D., Zhao, Y., Ren, Y., Ma, C., Chen, H., Li, M., Tian, J., Xue, C., Long, G., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1111430 · Cited by 59
Cheung, K. S., Ng, H. Y., Hui, R. W. H., Lam, L. K., Mak, L., Ho, Y. C., Tan, J. T., Chan, E. W., Seto, W., Yuen, M., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000855 · Cited by 56
Gries, J. J., Lazarus, J. V., Brennan, P., Siddiqui, M. S., Targher, G., Lang, C. C., Virani, S. S., Lavie, C. J., Isaacs, S. D., Arab, J. P., et al. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00310-8 · Cited by 59
Wang, X., Wu, N., Sun, C., Jin, D., & Lu, H. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01085-y · Cited by 54
Hüttl, M., Marková, I., Miklánková, D., Zapletalová, I., Poruba, M., Haluzı́k, M., Vaněčková, I., & Malínská, H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111513 · Cited by 51
Jin, Z., Yuan, Y., Chen, Z., Liu, S., & Weng, H. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108558 · Cited by 49
Chan, W., Tan, S.-S., Chan, S.-P., Lee, Y. Y., Tee, H., Mahadeva, S., Goh, K., Ramli, A. S., Mustapha, F. I., Kosai, N. R., et al. (2022) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15787 · Cited by 47
Antifibrotic therapies for metabolic dysfunction-associated steatotic liver disease
Schwabe, R. F., Tacke, F., Sugimoto, A., & Friedman, S. L. (2025) · JHEP Reports · doi:10.1016/j.jhepr.2025.101421 · Cited by 52
Cardiometabolic and renal benefits of sodium–glucose cotransporter 2 inhibitors
Lee, Y., Lim, S. K., & Davies, M. J. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01170-4 · Cited by 56
The Impact of an SGLT2 Inhibitor versus Ursodeoxycholic Acid on Liver Steatosis in Diabetic Patients
El-Hini, S. H., Wahsh, E. A., Elberry, A. A., Ameen, N. F. E., Saedii, A. A. F., Refaie, S. M., Elsayed, A. A., & Rabea, H. (2022) · Pharmaceuticals · doi:10.3390/ph15121516 · Cited by 49
Chadha, M. D., Das, A. K., Deb, P., Gangopadhyay, K. K., Joshi, S., Kesavadev, J., KOVIL, R. R., Kumar, S., Misra, A., & Mohan, V. (2022) · Diabetes Therapy · doi:10.1007/s13300-022-01219-x · Cited by 47
Bica, I.-C., Stoica, R. A., Salmen, T., Janež, A., Volčanšek, Š., Popovic, D. S., Muzurović, E. M., Rizzo, M., & Stoian, A. P. (2023) · Medicina · doi:10.3390/medicina59061136 · Cited by 42
Caturano, A., Galiero, R., Loffredo, G., Vetrano, E., Medicamento, G., Acierno, C., Rinaldi, L., Marrone, A., Salvatore, T., Monda, M., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11020322 · Cited by 43
Abdelhamid, A. M., Youssef, M. E., El-Fattah, E. E. A., Gobba, N. A., Gaafar, A. G. A., Girgis, S., Shata, A., Abdel-Moneim, A.-M. H., El-Ahwany, E. G., Amin, N. A., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.120070 · Cited by 42
Kongmalai, T., Srinonprasert, V., Anothaisintawee, T., Kongmalai, P., McKay, G. J., Attia, J., & Thakkinstian, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1182037 · Cited by 43
Gu, Y., Sun, L., Zhang, W., Kong, T., Zhou, R., He, Y., Deng, C., Yang, L., Kong, J., Chen, Y., et al. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1102792 · Cited by 46
Zhang, Y., Liu, X., Zhang, H., & Wang, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.836455 · Cited by 44
Deng, M., Wen, Y., Yan, J., Fan, Y., Wang, Z., Zhang, R., Ren, L., Ba, Y., Wang, H., Lü, Q., et al. (2023) · BMC Medicine · doi:10.1186/s12916-023-03129-6 · Cited by 40
Yan, H., Huang, C., Shen, X., Li, J., Zhou, S., & Li, W. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.923606 · Cited by 37
Lee, C., Mak, L., Tang, E. H. M., Lui, D. T. W., Mak, J. H., Li, L., Wu, T., Chan, W., Yuen, M., Lam, K. S. L., et al. (2023) · Hepatology · doi:10.1097/hep.0000000000000404 · Cited by 35
Chung, S. W., Moon, H.-S., Shin, H., Han, H., Park, S., Cho, H., Park, J., Hur, M. H., Park, M. K., Won, S., et al. (2024) · Hepatology · doi:10.1097/hep.0000000000000837 · Cited by 36
Perakakis, N., Chrysafi, P., Feigh, M., Veidal, S. S., & Mantzoros, C. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126332 · Cited by 34
The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review
Zachou, M., Flevari, P., Ansari, N. N., Varytimiadis, C., Kalaitzakis, E., Kassi, E. N., & Ανδρουτσάκος, Θ. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03586-1 · Cited by 38
SGLT2 inhibitors and AMPK: The road to cellular housekeeping?
Safaie, N., Masoumi, S., Alizadeh, S., Mirzajanzadeh, P., Nejabati, H. R., Hajiabbasi, M., Alivirdiloo, V., Basmenji, N. C., Radvar, A. D., Majidi, Z., et al. (2024) · Cell Biochemistry and Function · doi:10.1002/cbf.3922 · Cited by 32
Sun, L., Deng, C., Gu, Y., He, Y., Yang, L., & Shi, J. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.101876 · Cited by 31
Effects and potential mechanisms of IGF1/IGF1R in the liver fibrosis: A review
Gui, R., Li, W., Li, Z., Wang, H., Wu, Y., Jiao, W., Zhao, G., Shen, Y., Wang, L., Zhang, J., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.126263 · Cited by 32
Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease
Makri, E. S., Goulas, A., & Pοlyzos, S. A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174272 · Cited by 31
Effects of SGLT2 inhibitors on hepatic fibrosis and steatosis: A systematic review and meta-analysis
Zhou, P., Tan, Y., Hao, Z., Xu, W., Zhou, X., & Yu, J. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1144838 · Cited by 35
Luo, Q., Wei, R., Cai, Y., Zhao, Q., Liu, Y., & Liu, W. J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.793203 · Cited by 28
Liu, X., Chen, Y., Liu, T., Cai, L., Yang, X., & Mou, C. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1115321 · Cited by 29
Khamseh, M. E., Malek, M., Jahangiri, S., Nobarani, S., Hekmatdoost, A., Salavatizadeh, M., Soltanieh, S., Chehrehgosha, H., Taheri, H., Montazeri, Z., et al. (2024) · Digestive Diseases and Sciences · doi:10.1007/s10620-024-08309-9 · Cited by 26
Self-citationEmpagliflozin: a potential anticancer drug
Wu, W., Wang, Y., Xie, J., & Fan, S. (2023) · Discover Oncology · doi:10.1007/s12672-023-00719-x · Cited by 23
Cheng, P., Chen, W., Hou, C. J., Lin, C., Chang, M., Wang, C., Chang, W., Wang, C., Lin, C., Hung, C., et al. (2023) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2023.0315 · Cited by 25
Review of current and new drugs for the treatment of metabolic-associated fatty liver disease
Gish, R. G., Fan, J., Dossaji, Z., Fichez, J., Laeeq, T., Chun, M. J., & Boursier, J. (2024) · Hepatology International · doi:10.1007/s12072-024-10698-y · Cited by 24
Attaran, F., Emami, S., Sohrabi, M., Malek, M., Ajdarkosh, H., Khoonsari, M., Ismail-Beigi, F., & Khamseh, M. E. (2023) · BMC Gastroenterology · doi:10.1186/s12876-023-02948-4 · Cited by 22
Self-citationLi, H., Hou, Y., Xin, W., Ding, L., Yang, Y., Zhang, Y., Wu, W., Wang, Z., & Ding, W. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107647 · Cited by 22
Perdomo, C. M., Garcı́a-Fernández, N., & Escalada, J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10092040 · Cited by 21
Heo, Y.-J., Lee, N., Choi, S., Jeon, J., Han, S. J., Kim, D. J., KANG, Y. Y., Lee, K. W., & Kim, H. J. (2022) · Biomedicines · doi:10.3390/biomedicines10051032 · Cited by 21
Pokharel, A., Sudhamshu, K. C., Thapa, P., Karki, N., Shrestha, R., Jaishi, B., & Paudel, M. S. (2021) · Cureus · doi:10.7759/cureus.16687 · Cited by 22
SGLT-2 inhibitors as novel treatments of multiple organ fibrosis
Hu, J.-P., Teng, J., Hui, S., & Liang, L. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29486 · Cited by 21
Hameed, I., Hayat, J., Marsia, S., Samad, S. A., Khan, R., Siddiqui, O. M., Khan, M. O., Malik, S., Fatima, K., Fudim, M., et al. (2023) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102111 · Cited by 19
SGLT-2 Inhibitors for Non-Alcoholic Fatty Liver Disease: A Review
Xu, R., Lian, D., Xie, Y., Chen, Z., Wang, Y., Mu, L., Wang, Y., & Zhang, B. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2807134 · Cited by 22
Miklánková, D., Marková, I., Hüttl, M., & Malínská, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1393946 · Cited by 19
Khaliq, A., Badshah, H., Shah, Y., Rehman, I. U., Khan, K. U., Ming, L. C., & Cheng, M. H. (2024) · Medicine · doi:10.1097/md.0000000000040356 · Cited by 21
Zhang, F., Pan, X., Zhang, X., & Tong, N. (2023) · Obesity Reviews · doi:10.1111/obr.13675 · Cited by 19
Armandi, A., Bespaljko, H., Mang, A., Huber, Y., Michel, M. S., Labenz, C., Galle, P. R., Neerukonda, M., Bugianesi, E., Schuppan, D., et al. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17941 · Cited by 18
Shojaei, F., Erfanifar, A., Kalbasi, S., Nikpour, S., & Gachkar, L. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01882-8 · Cited by 17
Amin, M. A., Sadik, N. A., Saad, H. A., Fawzy, M., & Elsheimy, H. A. (2025) · Internal and Emergency Medicine · doi:10.1007/s11739-025-03902-w · Cited by 21
Al-Shargi, A., Kholy, A. A. E., Adel, A., Hassany, M., & Shaheen, S. M. (2023) · Biomedicines · doi:10.3390/biomedicines11113074 · Cited by 17
Weng, M., Yang, P., Liu, P.-F., Chang, C.-H., Lee, M., Sheu, J., & Nien, H. (2024) · Hepatology International · doi:10.1007/s12072-024-10758-3 · Cited by 16
Atherosclerosis and Non-Alcoholic Fatty Liver Disease
Balta, Ş. (2022) · Angiology · doi:10.1177/00033197221091317 · Cited by 16
Fakhrolmobasheri, M., Abhari, A. P., Manshaee, B., Heidarpour, M., Shafie, D., Mohammadbeigi, E., Mozafari, A. M., & Mazaheri‐Tehrani, S. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01981-1 · Cited by 17
Jahangiri, S., Malek, M., Kalra, S., & Khamseh, M. E. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01481-7 · Cited by 16
Self-citationElseweidy, M. M., Ali, A. A., Hassanin, S. M., & Mahmoud, Y. K. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02826-6 · Cited by 17
Lin, Y., Zhang, Z., Zhong, J.-Q., Wang, Z., Peng, Y.-T., Lin, Y.-M., Zhang, H.-P., & Tian, J.-Q. (2024) · PLoS ONE · doi:10.1371/journal.pone.0302155 · Cited by 17
Kawaguchi, T., Murotani, K., Kajiyama, H., Obara, H., Yamaguchi, H., Toyofuku, Y., Kaneko, F., Seino, Y., & Uchida, S. (2024) · Journal of Gastroenterology · doi:10.1007/s00535-024-02122-x · Cited by 17
Xu, R., Liu, B., & Zhou, X. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.11.017 · Cited by 16
Role of anti-diabetic medications in the management of MASLD
Isaacs, S. D., Farrelly, F. V., & Brennan, P. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2024-102856 · Cited by 19
Suki, M., Imam, A., Amer, J., Milgrom, Y., Massarwa, M., Hazou, W., Tiram, Y., Perzon, O., Sharif, Y., Sackran, J., et al. (2025) · Pharmaceuticals · doi:10.3390/ph18081118 · Cited by 17
Targeting Metabolism: Innovative Therapies for MASLD Unveiled
Wang, W., Gao, X., Niu, W., Yin, J., & He, K. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26094077 · Cited by 14
Hooshmand Gharabagh, L., Shargh, A., Mohammad Hosseini Azar, M. R., & Esmaeili, A. (2024) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102279 · Cited by 13
Ito, D., Inoue, K., Saito, D., Hamaguchi, K., Kaneko, K., Sumita, T., Inukai, K., Inoue, I., & Shimada, A. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01176-x · Cited by 13
Tang, X., Zhang, H., Wang, X., & Yang, D. (2022) · African Health Sciences · doi:10.4314/ahs.v22i3.42 · Cited by 12
Ciccarelli, G., Giuseppe, G. D., Cinti, F., Moffa, S., Mezza, T., & Giaccari, A. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3668 · Cited by 11
Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Risk of HF and AF
Ohno, R., Kaneko, H., Suzuki, Y., Okada, A., Matsuoka, S., Ueno, K., Fujiu, K., Michihata, N., Jo, T., Takeda, N., et al. (2023) · JACC Asia · doi:10.1016/j.jacasi.2023.08.003 · Cited by 11
Wang, H., Ma, Q., Chen, Y., Luo, L., Ye, J., & Zhong, B. (2024) · Obesity Reviews · doi:10.1111/obr.13727 · Cited by 15
Ntikoudi, A., Papachristou, A., Tsalkitzi, A., Margari, N., Evangelou, E., & Vlachou, E. D. (2025) · Diabetology · doi:10.3390/diabetology6040023 · Cited by 14
Sun, C., Goh, G. B., Chow, W. C., Chan, W., Wong, G. L., Seto, W., Huang, Y., Lin, H.-C., Lee, H. W., Lee, H. W., et al. (2023) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2023.08.004 · Cited by 10
Stan, S. I., Biciuşcă, V., Clenciu, D., Mitrea, A., Boldeanu, M. V., Durand, P., & Dănoiu, S. (2023) · Medicine and Pharmacy Reports · doi:10.15386/mpr-2629 · Cited by 14
Chai, S., Zhang, R., Ning, Z., Zheng, Y.-M., Rajpathak, S. N., & Ji, L. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i7.107335 · Cited by 10
Nani, A., Carrara, F., Paulesu, C. M. E., Fratte, C. D., Padroni, M., Enisci, S., Bilancio, M. C., Romio, M. S., Bertuzzi, F., & Pintaudi, B. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123958 · Cited by 10
Khaznadar, F., Petrovic, A., Khaznadar, O., Roguljić, H., Bojanić, K., Kuna, L., Siber, S., Smolić, R., Bilić-Čurčić, I., Wu, G. Y., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206561 · Cited by 12
Ren, Q., Tan, Y., Zhang, G., Dai, Y., Yang, L., Wu, Y., He, H., & Chen, J. (2025) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.70021 · Cited by 9
Insulin resistance: mechanisms and therapeutic interventions
Yu, L., Qian, J., Li, X., Tian, M., Bai, X., Yang, J., Deng, R., Lu, C., He, X., Lü, A., et al. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00408-5 · Cited by 12
Shi, R., Chai, K., Wang, H., Zhou, J., Yang, S., Li, J., Qiao, C., Sheng, X., Zhang, X., & Wu, J. (2025) · Journal of Evidence-Based Medicine · doi:10.1111/jebm.70002 · Cited by 9
Hossain, M. F., Khan, N. A., Rahman, A., Chowdhury, M. F. I., Bari, S., Khan, M. A., Masud, U. W., Zakia, U. B., Paul, S. P., & Tasnim, N. (2022) · Cureus · doi:10.7759/cureus.28367 · Cited by 8
Impact of SGLT2 Inhibitors on Lipoproteins in Type 2 Diabetes
Corral, P., Nardelli, N., Elbert, A. E., Aranguren, F., & Schreier, L. E. (2025) · Current Diabetes Reports · doi:10.1007/s11892-024-01572-0 · Cited by 7
Tan, Y., Qu, W., Zhao, J., Ma, Y., Zhang, Q., Gao, H., Zhen, Q., Wang, Y., Peng, Y., Liu, F., et al. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101680 · Cited by 7
Patmore, L. A., Carey, I., Feld, J. J., Brouwer, W. P., Patel, K., Buti, M., Honkoop, P., Postma, D. F., Blokzijl, H., Koc, Ö. M., et al. (2025) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.70360 · Cited by 7
Erfanifar, A., Nikpour, S., Davoudi, Z., Jolfaei, P., Toreyhi, H., & Nasab, S. N. M. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-02098-6 · Cited by 10
Yang, L., Ruan, J., Fang, Y., & Xu, A. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2025.1667823 · Cited by 7
Ogawa, Y., Nakahara, T., Ando, Y., Yamaoka, K., Fujii, Y., Uchikawa, S., Fujino, H., Ono, A., Murakami, E., Kawaoka, T., et al. (2023) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002588 · Cited by 8
Kaur, S., Sojitra, V., Zahra, A., Hutchinson, J., Folawemi, O., Bittla, P., & Ramphall, S. (2023) · Cureus · doi:10.7759/cureus.45789 · Cited by 7
Esmaeili, A., Azar, R. P., Hosseiniazar, M. M., & Gharabagh, L. H. (2024) · Journal of General and Family Medicine · doi:10.1002/jgf2.723 · Cited by 9
Pharmacotherapy for Non-alcoholic Fatty Liver Disease Associated with Diabetes Mellitus Type 2
Koullias, E., & Koskinas, J. S. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2021.00564 · Cited by 7
Metadata
- Authors
- Chehrehgosha, H., Sohrabi, M. R., Ismail-Beigi, F., Malek, M., Reza Babaei, M., Zamani, F., Ajdarkosh, H., Khoonsari, M., Fallah, A. E., & Khamseh, M. E.
- Affiliations
- Iran University of Medical Sciences (IR)
- Corresponding author
- Khamseh, Mohammad E.
- Venue
- Diabetes Therapy
- Published
- 2021-02-14
- Volume
- 12
- Issue
- 3
- Pages
- 843-861
- ISSN
- 1869-6953 (ISSN-L)
- 1869-6961
- PMC
- PMC7882235
- OpenAlex
- W3130225195
- Cited by
- 173
- References
- 86
- Citations by year
- 2026: 22 · 2025: 40 · 2024: 30 · 2023: 47 · 2022: 22 · 2021: 10
- FWCI
- 19.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diabetes Therapy (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Iran University of Medical Sciences
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Keywords
- empagliflozin, pioglitazone, non-alcoholic fatty liver disease, type 2 diabetes, hepatic steatosis, liver fibrosis, controlled attenuation parameter, liver stiffness measurement, FibroScan, visceral fat, body composition, insulin resistance, SGLT2 inhibitors, thiazolidinediones, antidiabetic drugs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
